⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for refractory glioma

Every month we try and update this database with for refractory glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250
Advanced Malign...
Recurrent Child...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Laboratory Biom...
Palbociclib
Pharmacological...
12 Months - 21 YearsNational Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)NCT03698994
Advanced Malign...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Wilms Tumor
Pharmacokinetic...
Ulixertinib
12 Months - 21 YearsNational Cancer Institute (NCI)
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBMNCT03149575
Glioblastoma Mu...
Glioblastoma
Glioma
GBM
Brain Cancer
VAL-083, Dianhy...
Physician's Cho...
Physician's Cho...
Physician's Cho...
18 Years - Kintara Therapeutics, Inc.
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)NCT03698994
Advanced Malign...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Wilms Tumor
Pharmacokinetic...
Ulixertinib
12 Months - 21 YearsNational Cancer Institute (NCI)
Safety Study of VAL-083 in Patients With Recurrent Malignant GliomaNCT01478178
Glioma
Glioblastoma
Glioblastoma Mu...
GBM
Brain Cancer
VAL-083 (Dianhy...
18 Years - Kintara Therapeutics, Inc.
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent SettingNCT02717962
Glioma
Glioblastoma
Glioblastoma Mu...
GBM
Brain Cancer
VAL-083, Dianhy...
18 Years - Kintara Therapeutics, Inc.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620
Advanced Malign...
Ann Arbor Stage...
Ann Arbor Stage...
Histiocytic Sar...
Juvenile Xantho...
Langerhans Cell...
Malignant Gliom...
Recurrent Child...
Recurrent Epend...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Prima...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Prim...
Refractory Rhab...
Refractory Rhab...
Rhabdoid Tumor
Stage III Osteo...
Stage III Soft ...
Stage IV Osteos...
Stage IV Soft T...
Stage IVA Osteo...
Stage IVB Osteo...
Wilms Tumor
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Bone Scan
Computed Tomogr...
Ensartinib
Erdafitinib
Laboratory Biom...
Larotrectinib S...
Magnetic Resona...
Mutation Carrie...
Olaparib
Palbociclib
Pharmacological...
Positron Emissi...
Radionuclide Im...
Samotolisib
Selpercatinib
Selumetinib Sul...
Tazemetostat
Tipifarnib
Ulixertinib
Vemurafenib
X-Ray Imaging
12 Months - 21 YearsNational Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250
Advanced Malign...
Recurrent Child...
Recurrent Ewing...
Recurrent Gliom...
Recurrent Hepat...
Recurrent Kidne...
Recurrent Lange...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Refractory Epen...
Refractory Ewin...
Refractory Glio...
Refractory Hepa...
Refractory Lang...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Laboratory Biom...
Palbociclib
Pharmacological...
12 Months - 21 YearsNational Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: